How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...

Recursion Pharmaceuticals uses its AI-driven platform to manage a deep pipeline of drug candidates through strategic partnerships with industry giants. Schrödinger leverages physics-based software to ...

The stage is set for the beginning of the tri-series between India A, Sri Lanka A, and Afghanistan A. The three sides will lock horns across several one-day matches before the two sides gather in the ...

Building a model capable of RSI would require automating a range of specialist tasks currently carried out by humans. At present data scientists work on the theory of AI and coders put it into ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Arthur Gies Arthur Gies is an editor for Wirecutter's tech coverage. He's ...